Zhitong Financial APP learned that Haitong International released a research report saying that the first hundred Ossets-B (02315) was "better than the market" rating, with a target price of HK $32.59, with 25.34% room for increase. Based on the core endowment of gene editing, the company has developed a variety of special model mice, and established a comprehensive pharmacological platform in 2015, combining the advantages of animal models to start preclinical research and services.

At the same time, it actively extended to the downstream field of innovative drug research and development, established Youhe Medicine in 2016, cut into innovative drug research and development, and put into operation Haimen Animal Center in the same year, with an annual production capacity of 800000 mice. Internationally, the plan of "thousands of mice" was put forward for the first time in 2020, which is still in steady progress, and more than 2021 innovative pipelines have made breakthroughs in clinical progress. In addition, it successfully logged into Hong Kong stock market in September 2022.